PortalPublikationenGATA3 Expression in Human Tumors: A Tissue Microarray Study ...

GATA3 Expression in Human Tumors: A Tissue Microarray Study on 16,557 Tumors

Standard

GATA3 Expression in Human Tumors: A Tissue Microarray Study on 16,557 Tumors. / Reiswich, Viktor; Schmidt, Carol E; Lennartz, Maximilian; Höflmayer, Doris; Hube-Magg, Claudia; Weidemann, Sören; Fraune, Christoph; Büscheck, Franziska; Möller, Katharina; Bernreuther, Christian; Simon, Ronald; Clauditz, Till S; Blessin, Niclas C; Bady, Elena; Sauter, Guido; Uhlig, Ria; Steurer, Stefan; Minner, Sarah; Burandt, Eike; Dum, David; Marx, Andreas H; Krech, Till; Lebok, Patrick; Hinsch, Andrea; Jacobsen, Frank.

in: PATHOBIOLOGY, Jahrgang 90, Nr. 4, 2023, S. 219-232.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Reiswich, V, Schmidt, CE, Lennartz, M, Höflmayer, D, Hube-Magg, C, Weidemann, S, Fraune, C, Büscheck, F, Möller, K, Bernreuther, C, Simon, R, Clauditz, TS, Blessin, NC, Bady, E, Sauter, G, Uhlig, R, Steurer, S, Minner, S, Burandt, E, Dum, D, Marx, AH, Krech, T, Lebok, P, Hinsch, A & Jacobsen, F 2023, 'GATA3 Expression in Human Tumors: A Tissue Microarray Study on 16,557 Tumors', PATHOBIOLOGY, Jg. 90, Nr. 4, S. 219-232. https://doi.org/10.1159/000527382

APA

Reiswich, V., Schmidt, C. E., Lennartz, M., Höflmayer, D., Hube-Magg, C., Weidemann, S., Fraune, C., Büscheck, F., Möller, K., Bernreuther, C., Simon, R., Clauditz, T. S., Blessin, N. C., Bady, E., Sauter, G., Uhlig, R., Steurer, S., Minner, S., Burandt, E., ... Jacobsen, F. (2023). GATA3 Expression in Human Tumors: A Tissue Microarray Study on 16,557 Tumors. PATHOBIOLOGY, 90(4), 219-232. https://doi.org/10.1159/000527382

Vancouver

Reiswich V, Schmidt CE, Lennartz M, Höflmayer D, Hube-Magg C, Weidemann S et al. GATA3 Expression in Human Tumors: A Tissue Microarray Study on 16,557 Tumors. PATHOBIOLOGY. 2023;90(4):219-232. https://doi.org/10.1159/000527382

Bibtex

@article{159a912deafd41dca6ebb7d2218aa2e1,
title = "GATA3 Expression in Human Tumors: A Tissue Microarray Study on 16,557 Tumors",
abstract = "INTRODUCTION: GATA3 is a transcription factor involved in epithelial cell differentiation. GATA3 immunostaining is used as a diagnostic marker for breast and urothelial cancer but can also occur in other neoplasms.METHODS: To evaluate GATA3 in normal and tumor tissues, a tissue microarray containing 16,557 samples from 131 different tumor types and subtypes and 608 samples of 76 different normal tissue types was analyzed by immunohistochemistry.RESULTS: GATA3 positivity was found in 69 different tumor types including 23 types (18%) with at least one strongly positive tumor. Highest positivity rates occurred in noninvasive papillary urothelial carcinoma (92-99%), lobular carcinoma (98%), carcinoma of no special type of the breast (92%), basal cell carcinoma of the skin (97%), invasive urothelial carcinoma (73%), T-cell lymphoma (23%), adenocarcinoma of the salivary gland (16%), squamous cell carcinoma of the skin (16%), and colorectal neuroendocrine carcinoma (12%). In breast cancer, low GATA3 staining was linked to high pT stage (p = 0.03), high BRE grade (p < 0.0001), HER2 overexpression (p = 0.0085), estrogen and progesterone receptor negativity (p < 0.0001 each), and reduced survival (p = 0.03).CONCLUSION: Our data demonstrate that GATA3 positivity can occur in various tumor entities. Low levels of GATA3 reflect cancer progression and poor patient prognosis in breast cancer.",
author = "Viktor Reiswich and Schmidt, {Carol E} and Maximilian Lennartz and Doris H{\"o}flmayer and Claudia Hube-Magg and S{\"o}ren Weidemann and Christoph Fraune and Franziska B{\"u}scheck and Katharina M{\"o}ller and Christian Bernreuther and Ronald Simon and Clauditz, {Till S} and Blessin, {Niclas C} and Elena Bady and Guido Sauter and Ria Uhlig and Stefan Steurer and Sarah Minner and Eike Burandt and David Dum and Marx, {Andreas H} and Till Krech and Patrick Lebok and Andrea Hinsch and Frank Jacobsen",
note = "{\textcopyright} 2023 S. Karger AG, Basel.",
year = "2023",
doi = "10.1159/000527382",
language = "English",
volume = "90",
pages = "219--232",
journal = "PATHOBIOLOGY",
issn = "1015-2008",
publisher = "S. Karger AG",
number = "4",

}

RIS

TY - JOUR

T1 - GATA3 Expression in Human Tumors: A Tissue Microarray Study on 16,557 Tumors

AU - Reiswich, Viktor

AU - Schmidt, Carol E

AU - Lennartz, Maximilian

AU - Höflmayer, Doris

AU - Hube-Magg, Claudia

AU - Weidemann, Sören

AU - Fraune, Christoph

AU - Büscheck, Franziska

AU - Möller, Katharina

AU - Bernreuther, Christian

AU - Simon, Ronald

AU - Clauditz, Till S

AU - Blessin, Niclas C

AU - Bady, Elena

AU - Sauter, Guido

AU - Uhlig, Ria

AU - Steurer, Stefan

AU - Minner, Sarah

AU - Burandt, Eike

AU - Dum, David

AU - Marx, Andreas H

AU - Krech, Till

AU - Lebok, Patrick

AU - Hinsch, Andrea

AU - Jacobsen, Frank

N1 - © 2023 S. Karger AG, Basel.

PY - 2023

Y1 - 2023

N2 - INTRODUCTION: GATA3 is a transcription factor involved in epithelial cell differentiation. GATA3 immunostaining is used as a diagnostic marker for breast and urothelial cancer but can also occur in other neoplasms.METHODS: To evaluate GATA3 in normal and tumor tissues, a tissue microarray containing 16,557 samples from 131 different tumor types and subtypes and 608 samples of 76 different normal tissue types was analyzed by immunohistochemistry.RESULTS: GATA3 positivity was found in 69 different tumor types including 23 types (18%) with at least one strongly positive tumor. Highest positivity rates occurred in noninvasive papillary urothelial carcinoma (92-99%), lobular carcinoma (98%), carcinoma of no special type of the breast (92%), basal cell carcinoma of the skin (97%), invasive urothelial carcinoma (73%), T-cell lymphoma (23%), adenocarcinoma of the salivary gland (16%), squamous cell carcinoma of the skin (16%), and colorectal neuroendocrine carcinoma (12%). In breast cancer, low GATA3 staining was linked to high pT stage (p = 0.03), high BRE grade (p < 0.0001), HER2 overexpression (p = 0.0085), estrogen and progesterone receptor negativity (p < 0.0001 each), and reduced survival (p = 0.03).CONCLUSION: Our data demonstrate that GATA3 positivity can occur in various tumor entities. Low levels of GATA3 reflect cancer progression and poor patient prognosis in breast cancer.

AB - INTRODUCTION: GATA3 is a transcription factor involved in epithelial cell differentiation. GATA3 immunostaining is used as a diagnostic marker for breast and urothelial cancer but can also occur in other neoplasms.METHODS: To evaluate GATA3 in normal and tumor tissues, a tissue microarray containing 16,557 samples from 131 different tumor types and subtypes and 608 samples of 76 different normal tissue types was analyzed by immunohistochemistry.RESULTS: GATA3 positivity was found in 69 different tumor types including 23 types (18%) with at least one strongly positive tumor. Highest positivity rates occurred in noninvasive papillary urothelial carcinoma (92-99%), lobular carcinoma (98%), carcinoma of no special type of the breast (92%), basal cell carcinoma of the skin (97%), invasive urothelial carcinoma (73%), T-cell lymphoma (23%), adenocarcinoma of the salivary gland (16%), squamous cell carcinoma of the skin (16%), and colorectal neuroendocrine carcinoma (12%). In breast cancer, low GATA3 staining was linked to high pT stage (p = 0.03), high BRE grade (p < 0.0001), HER2 overexpression (p = 0.0085), estrogen and progesterone receptor negativity (p < 0.0001 each), and reduced survival (p = 0.03).CONCLUSION: Our data demonstrate that GATA3 positivity can occur in various tumor entities. Low levels of GATA3 reflect cancer progression and poor patient prognosis in breast cancer.

U2 - 10.1159/000527382

DO - 10.1159/000527382

M3 - SCORING: Journal article

C2 - 36649695

VL - 90

SP - 219

EP - 232

JO - PATHOBIOLOGY

JF - PATHOBIOLOGY

SN - 1015-2008

IS - 4

ER -